Decades of experience give us valuable perspectives and enable us to provide critical insights into the challenges and trends facing the biopharmaceutical industry.
SKYSIS WEBINAR SERIES: WHO LET THE DOGS OUT? STRATEGIES FOR OUTSOURCING TAIL PRODUCTS
Pharmaceutical companies are often burdened with maintaining products (“Tail Products”) that are not strategic to future growth. Tail Products may come from acquisitions or could be relics from a prior phase in a company’s lifecycle.
This webinar focuses on defining the Tail Products Challenge and assessing possible solutions.
This White Paper looks at four major themes that can help Life Science sales and marketing decision makers differentiate and gain competitive advantage in the marketplace. These themes include:
• Identifying Obvious and Non-Obvious Sources of Data
• Assessing and Sharing Data Across Internal/External Silos
• Interpreting Data and Drawing Meaningful Insights from Analysis
• Applying Data Insights, Modifying Investments and Measuring Performance
KEY CONSIDERATIONS WHEN BUILDING A ROBUST GROSS-TO-NET FINANCIAL MODEL
Net product sales is the primary metric for which the success or failure of a company’s commercial efforts are measured. Investors expect a correlation between prescriptions (readily available and reported by Symphony or IMS) and the net product sales that a company reports on a quarterly basis. Deviations between prescription growth and reported net product sales often require an explanation.
The attached White Paper provides extensive detail and commentary around some of the key activities that impact a company’s Gross-to-Net management.
